Mechanisms of microbial interactions between probiotic microorganisms and Helicobacter pylori | CMAC

Mechanisms of microbial interactions between probiotic microorganisms and Helicobacter pylori

Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(3):225-238

​ Isaeva G.Sh., Isaeva R.A.
10.36488/cmac.2023.3.225-238
Helicobacter pylori microbiota probiotics
Section
Diseases and Pathogens
Type
Review
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(3):225-238

Abstract

This review summarizes the most recent data about the mechanisms of microbial interactions between probiotic microorganisms and H. pylori. The review examines the influence of H. pylori on the gastrointestinal microbiota, interspecific interactions of microorganisms in microbial consortia, mechanisms of antagonistic action of probiotic cultures on H. pylori, as well as the analysis of experience of using probiotics in the treatment of helicobacteriosis. At the same time, there will be many unresolved questions about the choice of the specific composition of the probiotic cocktail, dosage, duration of therapy, mechanisms of antimicrobial action of probiotics, as well as possible negative sides of this therapy, which requires further research.

Guzel Sh. Isaeva

Kazan Research Institute of Epidemiology and Microbiology, Kazan, Russia
Kazan State Medical University, Kazan, Russia

Isaeva R.A.

Kazan Research Institute of Epidemiology and Microbiology, Kazan, Russia
Kazan State Medical University, Kazan, Russia

  • 1. Nakamura M., Murayama S.Y., Rimbara E. Review: nonHelicobacter pylori Helicobacters. Microb Health Dis. 2022;4(3):723. DOI: 10.26355/mhd_20229_723
  • 2. Sugano K., Tack J., Kuipers E.J., Graham D.Y., El-Omar E.M., Miura S., et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64: 1353-1367. DOI: 10.1136/gutjnl-2015-309252
  • 3. O’Connor A. Review: treatment of Helicobacter pylori infection 2022. Microb Health Dis. 2022;4(3):e713. DOI: 10.26355/mhd_20229_713
  • 4. Azadbakht S., Moayyedkazemi A., Azadbakht S., Fard S.A., Soroush S. Evaluation of antibiotic resistance of Helicobacter pylori bacteria obtained from gastric biopsy samples: a cohort study. Ann Med Surg (Lond). 2022;78:103824. DOI: 10.1016/j.amsu.2022.103824
  • 5. Tian L., Yao Y., Yin L., Wang L., An Z., Kang L., et al. Direct detection of antibiotic resistance in Chinese Helicobacter pylori clinical isolates by sequencing-based approach. J Healthc Eng. 2022;2022:6436256. DOI: 10.1155/2022/6436256
  • 6. Vanden Bulcke A., Waked B., Haems L., Lambrecht G., Hervent A. S., Alliet G., Baert F., et al. Antimicrobial resistance of Helicobacter pylori in West Flanders – Belgium: an observational cross-sectional study. Acta Clin Belg. 2022;77(2):360-367. DOI: 10.1080/17843286.2021.1872307
  • 7. Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T., et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. DOI: 10.1136/gutjnl-2016-312288
  • 8. Malfertheiner P., Megraud F., Rokkas T., Gisbert P.J., Liou J.M., Schulz C., et al. Management of Helicobacter pylori infection – the Maastricht VI/Florence Consensus Report. Gut. 2022; gutjnl-2022-327745. DOI: 10.1136/gutjnl-2022-327745
  • 9. Stoma I.O. Microbiome in medicine: a guidance for doctors. GEOTAR-Media 2020. 320 p. Russian.
  • 10. Schulz C., Schutte K., Malfertheiner P. Helicobacter pylori and other gastric microbiota in gastroduodenal pathologies. Dig Dis. 2016;34:210-216. DOI: 10.1159/000443353
  • 11. Zilberstein B., Quintanilha A.G., Santos M.A., Pajecki D., Moura E.G, Alves P.R.A., et al. Digestive tract microbiota in healthy volunteers. Clinics (Sao Paulo). 2007;62(1):4754. DOI: 10.1590/s1807-59322007000100008
  • 12. Delgado S., Cabrera-Rubio R., Mira A., Suarez A., Mayo B. Microbiological survey of the human gastric ecosystem using culturing and pyrosequencing methods. Microb Ecol. 2013;65(3):763-772. DOI: 10.1007/s00248-013-0192-5
  • 13. Bik E.M., Eckburg P.B., Gill S.R., Nelson K.E., Purdom E.A., Francois F., et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci U S A. 2006;103(3):732-737. DOI: 10.1073/pnas.0506655103
  • 14. Li X.X., Wong G.L., To K.F., Wong V.W.S., Lai L.H., Chow D.K.L., et al. Bacterial microbiota profiling in gastritis without Helicobacter pylori infection or non-steroidal antiinflammatory drug use. PLoS One. 2009;4(11):e7985. DOI: 10.1371/journal.pone.0007985
  • 15. Nicholson J.K., Holmes E., Kinross J., Burcelin R., Gibson G., Jia W., et al. Host-gut microbiota metabolic interactions. Science. 2012;336(6086):1262-1267. DOI: 10.1126/science.1223813
  • 16. Maldonado-Contreras A., Goldfarb K.C., Godoy-Vitorino F., Karaoz U., Contreras M., Blaser M.J., et al. Structure of the human gastric bacterial community in relation to Helicobacter pylori status. ISME J. 2011;5(4):574-579. DOI: 10.1038/ismej.2010.149
  • 17. Shin C.M., Kim N., Ji Hyun Park J.H., Lee D.H. Changes in gastric corpus microbiota with age and after Helicobacter pylori eradication: a long-term follow-up study. Front Microbiol. 2021;11:621879. DOI: 10.3389/fmicb.2020.621879
  • 18. Espinoza J.L., Matsumoto A., Tanaka H., Matsumura I. Gastric microbiota: an emerging player in Helicobacter pyloriinduced gastric malignancies. Cancer Lett. 2018;414:147152. DOI: 10.1016/j.canlet.2017.11.009
  • 19. Schulz C., Schutte K., Koch N., Vilchez-Vargas R., WosOxley M.L., Oxley A.P.A., et al. The active bacterial assemblages of the upper GI tract in individuals with and without Helicobacter infection. Gut. 2018;67(2):216225. DOI: 10.1136/gutjnl-2016-312904
  • 20. Aebischer T., Fischer A., Walduck A., Schlotelburg C., Lindig M., Schreiber S., et al. Vaccination prevents Helicobacter pylori-induced alterations of the gastric flora in mice. FEMS Immunol Med Microbiol. 2006;46(2):221229. DOI: 10.1111/j.1574-695X.2005.00024.x
  • 21. Kienesberger S., Cox L.M., Livanos A., Zhang X.S., Chung, J., Guillermo, I., et al. Gastric Helicobacter pylori infection affects local and distant microbial populations and host responses. Cell Rep. 2016;14(6):1395-1407. DOI: 10.1016/j.celrep.2016.01.017
  • 22. Myllyluoma E., Ahlroos T., Veijola L., Rautelin H., Tynkkynen S., Korpela R. Effects of anti-Helicobacter pylori treatment and probiotic supplementation on intestinal microbiota. Int J Antimicrob Agents. 2007;29(1):66-72. DOI: 10.1016/j.ijantimicag.2006.08.034
  • 23. Jakobsson H.E., Jernberg C., Andersson A.F., SjolundKarlsson M., Jansson J.K., Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One. 2010;5(3):e9836. DOI: 10.1371/journal.pone.0009836
  • 24. Chen L., Xu W., Lee A., He J., Huang B., Zheng W., et al. The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: an open-label, randomized clinical trial. EBioMedicine. 2018;35:87-96. DOI: 10.1016/j.ebiom.2018.08.028
  • 25. Olekhnovich E.I., Manolov A.I., Samoilov A.E., Prianichnikov N.A., Malakhova, M.V., Tyakht A.V., et al. Shifts in the human gut microbiota structure caused by quadruple Helicobacter pylori eradication therapy. Front Microbiol. 2019;10:1902. DOI: 10.3389/fmicb.2019.01902
  • 26. Smirnov V.V., Kovalenko N.K., Podgorskii S., Sorokulova I.B. Probiotics based on live cultures of microorganisms. Mikrobiologicheskij zhurnal. 2002;64(4):62-80. Russian.
  • 27. Araya M., Morelli L., Reid G., Sanders M.E., Stanton C., Pineiro M., et al. Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food, 2002. Available at: www.mhlw.go.jp/file/05-Shingikai-11121000-IyakushokuhinkyokuSoumuka/0000197343.pdf. Accessed August 2023.
  • 28. Jezewska-Frackowiak J., Seroczynska K., Banaszczyk J., Jedrzejczak G., Zylicz-Stachula A., Skowron P.M. The promises and risks of probiotic Bacillus species. Acta Biochim Pol. 2018;65(4):509-519. DOI: 10.18388/abp.2018_2652
  • 29. Ryan K.A., Jayaraman T., Daly P., Canchaya C., Curran S., Fang F., et al. Isolation of lactobacilli with probiotic properties from the human stomach. Lett Appl Microbiol. 2008;47(4):269-274. DOI: 10.1111/j.1472765x.2008.02416.x
  • 30. Chen Y.H., Tsai W.H., Wu H.Y., Chen C.Y., Yeh W.L., Chen Y.H., et al. Probiotic spp. act against Helicobacter pylori-induces inflammation. J Clin Med. 2019;8(1):90. DOI: 10.3390/jcm8010090
  • 31. Zhao K., Xie Q., Xu D., Guo Y., Tao X., Wei H., et al. Antagonistics of Lactobacillus plantarum ZDY2013 against Helicobacter pylori SS1 and its infection in vitro in human gastric epithelial AGS cells. J Biosci Bioeng. 2018;126(4):458-463. DOI: 10.1016/j.jbiosc.2018.04.003
  • 32. Sun L., Zhao H., Liu L., Wu X., Gao Q., Zhao Y. Effects of Lactobacillus on the inhibition of Helicobacter pylori growth. Biotechnol Biotechnol Equip. 2018;32(6):15331540. DOI: 10.1080/13102818.2018.1515599
  • 33. Bhatia S.J., Kochar N., Abraham P., Nair N.G., Mehta A.P. Lactobacillus acidophilus inhibits growth of Campylobacter pylori in vitro. J Clin Microbiol. 1989;27(10):2328-2330. DOI: 10.1128/jcm.27.10.2328-2330.1989
  • 34. Aiba Y., Nakano Y., Koga Y., Takahashi K., Komatsu Y. A highly acid-resistant novel strain of Lactobacillus johnsonii No. 1088 has antibacterial activity, including that against Helicobacter pylori, and inhibits gastrin-mediated acid production in mice. Microbiologyopen. 2015;4(3):465474. DOI: 10.1002/mbo3.252
  • 35. Aiba Y., Ishikawa H., Tokunaga M., Komatsu Y. AntiHelicobacter pylori activity of non-living, heat-killed form of lactobacilli including Lactobacillus johnsonii No.1088. FEMS Microbiol Lett. 2017;364(11). DOI: 10.1093/femsle/fnx102
  • 36. Zheng P.X., Fang H.Y., Yang H.B., Tien N.Y., Wang M.C., Wu J.J. Lactobacillus pentosus strain LPS16 produces lactic acid, inhibiting multidrug-resistant Helicobacter pylori. J Microbiol Immunol Infect. 2016;49(2):168-174. DOI: 10.1016/j.jmii.2014.04.014
  • 37. Lesbros-Pantoflickova D., Corthesy-Theulaz I., Blum A.L. Helicobacter pylori and probiotics. J Nutr. 2007;137(3 Suppl. 2):812S-8S. DOI: 10.1093/jn/137.3.812S
  • 38. Batdorj B., Trinetta V., Dalgalarrondo M., Prevost H., Dousset X., Ivanova I., et al. Isolation, taxonomic identification and hydrogen peroxide production by Lactobacillus delbrueckii subsp lactis T31, isolated from Mongolian yoghurt: Inhibitory activity on food-borne pathogens foolborne pathogens. J Appl Microbiol. 2007;103(3):584593. DOI: 10.1111/j.1365-2672.2007.03279.x
  • 39. Kim N.N., Kim W.J., Kang S.S. Anti-biofilm effect of crude bacteriocin derived from Lactobacillus brevis DF01 on Escherichia coli and Salmonella Typhimurium. Food Control. 2018;98:274-280. DOI: 10.1016/j.foodcont.2018.11.004
  • 40. Kim T.S., Hur J.W., Yu M.A., Cheigh C.I., Kim K.N., Hwang J.K., et al. Antagonism of Helicobacter pylori by bacteriocins of lactic acid bacteria. J Food Prot. 2003;66(1):3-12. DOI: 10.4315/0362-028x-66.1.3
  • 41. Boyanova L., Gergova G., Markovska R., Yordanov D., Mitov I. Bacteriocin-like inhibitory activities of seven Lactobacillus delbrueckii subsp. bulgaricus strains against antibiotic susceptible and resistant Helicobacter pylori strains. Lett Appl Microbiol. 2017;65(6):469-474. DOI: 10.1111/lam.12807
  • 42. Urrutia-Baca V.H., Escamilla-Garcia E., de la GarzaRamos M.A., Tamez-Guerra P., Gomez-Flores R., UrbinaRios C.S. In vitro antimicrobial activity and downregulation of virulence gene expression on Helicobacter pylori by reuterin. Probiotics Antimicrob Proteins. 2018;10(2):168175. DOI: 10.1007/s12602-017-9342-2
  • 43. Mukai T., Asasaka T., Sato E., Mori K., Matsumoto M., Ohori H. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. Fems Immunol Med Microbiol. 2002;32(2):105-110. DOI: 10.1111/j.1574-695X.2002.tb00541.x
  • 44. De Klerk N., Maudsdotter L., Gebreegziabher H., Sa_ roj S.D., Eriksson B., Eriksson O.S., et al. Lactobacilli reduce Helicobacter pylori attachment to host gastric epithelial cells by inhibiting adhesion gene expression. Infect Immun. 2016;84(5):1526-1535. DOI: 10.1128/IAI.00163-16
  • 45. Sakarya S., Gunay N. Saccharomyces boulardii expresses neuraminidase activity selective for alpha2,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells. APMIS. 2014;122(10):941-950. DOI: 10.1111/apm.12237
  • 46. Mack D., Ahrne S., Hyde L., Wei S., Hollingsworth M.A. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut. 2003;52(6):827-833. DOI: 10.1136/gut.52.6.827
  • 47. Byrd J.C., Yunker C.K., Xu Q.S., Sternberg L.R., Bresalier R.S. Inhibition of gastric mucin synthesis by Helicobacter pylori. Gastroenterology. 2000;118(6):1072-1079. DOI: 10.1016/s0016-5085(00)70360-x
  • 48. Hanisch F.G., Bonar D., Schloerer N., Schroten H. Human trefoil factor 2 isa lectin that binds α-GlcNAc-capped mucinglycans with antibiotic activity against Helicobacter pylori. J Biol Chem. 2014;289(40):27363-27375. DOI: 10.1074/jbc.M114.597757
  • 49. Suez J., Zmora N., Segal E., Elinav E. The pros, cons, and many unknowns of probiotics. Nat Med. 2019;25(5):716729. DOI: 10.1038/s41591-019-0439-x
  • 50. Yang Y.J., Chuang C.C., Yang H.B., Lu C.C., Sheu B.S. Lactobacillus acidophilus ameliorates H. pylori-induced gastric inflammation by inactivating the Smad7 and NFKB pathways. BMC Microbiol. 2012;12:38. DOI: 10.1186/1471-2180-12-38
  • 51. Thiraworawong T., Spinler J.K., Werawatganon D., Klaikeaw N., Venable S.F., Versalovic J., et al. Antiinflammatory properties of gastric-derived Lactobacillus plantarum XB7 in the context of Helicobacter pylori infection. Helicobacter. 2014;19(2):144-155. DOI: 10.1111/hel.12105
  • 52. Song H., Zhou L., Liu D., Ge L., Li Y. Probiotic effect on Helicobacter pylori attachment and inhibition of inflammation in human gastric epithelial cells. Exp Ther Med. 2019;18(3):1551-1562. DOI: 10.3892/etm.2019.7742
  • 53. Wiese M., Eljaszewicz A., Andryszczyk M., Gronek S., Gackowska L., Kubiszewska I., et al. Immunomodulatory effects of Lactobacillous plantarum and Helicobacter pylori CagA+ on the expression of selected superficial molecules on monocyte and lymphocyte and the synthesis of cytokines in whole blood culture. J Physiol Pharmacol. 2012;63(3):217-224. PMID: 22791635.
  • 54. Zhou C., Ma F.Z., Deng X.J., Yuan H., Ma H.S. Lactobacilli inhibit interleukin-8 production induced by Helicobacter pylori lipopolysaccharide-activated Toll-like receptor 4. World J Gastroenterol. 2008;14(32):5090-5095. DOI: 10.3748/wjg.14.5090
  • 55. Miller M.B., Bassler B.L. Quorum sensing in bacteria. Annu Rev Microbiol. 2001;55:165-199. DOI: 10.1146/annurev.micro.55.1.165
  • 56. Sun J., Daniel R., Wagner-Dobler I., Zeng A.P. Is autoinducer-2 a universal signal for interspecies communication: a comparative genomic and phylogenetic analysis of the synthesis and signal transduction pathways. BMC Evol Biol. 2004;4:36. DOI: 10.1186/1471-21484-36
  • 57. Joyce E.A., Bassler B.L., Wright A. Evidence for a signaling system in Helicobacter pylori: detection of a luxS-encoded autoinducer. J Bacteriol. 2000;182(13):3638-3643. DOI: 10.1128/JB.182.13.3638-3643.2000
  • 58. Stark R.M., Gerwig G.J., Pitman R.S., Potts L.F., Williams N.A., Greenman J., et al. Biofilm formation by Helicobacter pylori. Lett Appl Microbiol. 1999;28:121126. DOI: 10.1046/j.1365-2672.1999.00481.x
  • 59. Yonezawa H., Osaki T., Kurata S., Zaman C., Hanawa T., Kamiya S. Assessment of in vitro biofilm formation by Helicobacter pylori. J Gastroenterol Hepatol. 2010;25(Suppl. 1):S90-4. DOI: 10.1111/j.14401746.2009.06213.x
  • 60. Yonezawa H., Osaki T., Kurata S., Fukuda M., Kawakami H., Ochiai K., et al. Outer membrane vesicles of Helicobacter pylori TK1402 are involved in biofilm formation. BMC Microbiol. 2009;9:197. DOI: 10.1186/1471-2180-9197
  • 61. Williams J.C., McInnis K.A., Testerman T.L. Adherence of Helicobacter pylori to abiotic surfaces is influenced by serum. Appl Environ Microbiol. 2008;74(4):1255-1258. DOI: 10.1128/AEM.01958-07
  • 62. Swidsinski A., Loening-Baucke V., Herber A. Mucosal flora in Crohn’s disease and ulcerative colitis – an overview. J Physiol Pharmacol. 2009;60(Suppl. 6):61-71. PMID: 20224153.
  • 63. Carron M.A., Tran V.R., Sugawa C., Coticchia J.M. Identification of Helicobacter pylori biofilms in human gastric mucosa. J Gastrointest Surg. 2006;10(5):712-717. DOI: 10.1016/j.gassur.2005.10.019
  • 64. Cellini L., Grande R., Di Campli E., Traini T., Di Giulio M., Lannutti S.N., et al. Dynamic colonization of Helicobacter pylori in human gastric mucosa. Scand J Gastroenterol. 2008;43(2):178-185. DOI: 10.1080/00365520701675965
  • 65. Coticchia J.M., Sugawa C., Tran V.R., Gurrola J., Kowalski E., Carron M.A. Presence and density of Helicobacter pylori biofilms in human gastric mucosa in patients with peptic ulcer disease. J Gastrointest Surg. 2006;10(6):883889. DOI: 10.1016/j.gassur.2005.12.009
  • 66. Yonezawa H., Osaki T., Hojo F., Kamiya S. Effect of Helicobacter pylori biofilm formation on susceptibility to amoxicillin, metronidazole and clarithromycin. Microb Pathog. 2019;132:100-108. DOI: 10.1016/j.micpath.2019.04.030
  • 67. Attaran B., Falsafi T., Ghorbanmehr N. Effect of biofilm formation by clinical isolates of Helicobacter pylori on the efflux-mediated resistance to commonly used antibiotics. World J Gastroenterol. 2017;23(7):1163-1170. DOI: 10.3748/wjg.v23.i7.1163
  • 68. Yonezawa H., Osaki T., Hanawa T., Kurata S., Ochiai K., Kamiya S. Impact of Helicobacter pylori biofilm formation on clarithromycin susceptibility and generation of resistance mutations. PLoS One. 2013;8(9):e73301. DOI: 10.1371/journal.pone.0073301
  • 69. Ge X., Cai Y., Chen Z., Gao S., Geng X., Li Y., et al. Bifunctional enzyme spot is involved in biofilm formation of Helicobacter pylori with multidrug resistance by upregulating efflux pump Hp1174 (gluP). Antimicrob Agents Chemother. 2018;62(11):e00957-18. DOI: 10.1128/AAC.00957-18
  • 70. Hathroubi S., Servetas S.L., Windham I., Merrell D.S., Ottemann K.M. Helicobacter pylori biofilm formation and its potential role in pathogenesis. Microbiol Mol Biol Rev. 2018;82(2):e00001-18. DOI: 10.1128/MMBR.00001-18
  • 71. Hathroubi S., Zerebinski J., Ottemann K.M. Helicobacter pylori biofilm involves a multigene stress-biased response, including a structural role for flagella. mBio. 2018;9(5):e01973-18. DOI: 10.1128/mBio.01973-18
  • 72. Cammarota G., Branca G., Ardito F., Ianiro G., Cianci R., Torelli R, et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol. 2010;8(9):817-820.e3. DOI: 10.1016/j.cgh.2010.05.006
  • 73. Song H., Zhang, J., Qu J., Liu J., Yin P., Zhang G., et al. Lactobacillus rhamnosus GG microcapsules inhibit Escherichia coli biofilm formation in coculture. Biotechnol Lett. 2019;41(8-9):1007-1014. DOI: 10.1007/s10529019-02694-2
  • 74. Merino L., Trejo F.M., De Antoni G., Golowczyc M.A. Lactobacillus strains inhibit biofilm formation of Salmonella sp. isolates from poultry. Food Res Int. 2019;123:258265. DOI: 10.1016/j.foodres.2019.04.067
  • 75. Jung S., Park O.J., Kim A.R., Ahn K.B., Lee D., Kum K.Y., et al. Lipoteichoic acids of lactobacilli inhibit Enterococcus faecalis biofilm formation and disrupt the preformed biofilm. J Microbiol. 2019;57(4):310-315. DOI: 10.1007/s12275-019-8538-4
  • 76. Gonzalez Moreno M., Trampu A., Di Luca M. Synergistic antibiotic activity against planktonic and biofilm-embedded Streptococcus agalactiae, Streptococcus pyogenes and Streptococcus oralis. J Antimicrob Chemother. 2017;72(11):3085-3092. DOI: 10.1093/jac/dkx265
  • 77. Moghadam S.S., Khodaii Z., Zadeh F.S., Ghooshchian M., Aghmiyuni F.Z., Shabestari M.T. Synergistic or antagonistic effects of probiotics and antibiotics-alone or in combination-on antimicrobial-resistant Pseudomonas aeruginosa isolated from burn wounds. Arch Clin Infect Dis. 2018;3(3):e63121. DOI: 10.5812/archcid.6312
  • 78. Yang J., Yang H. Effect of Bifidobacterium breve in combination with different antibiotics on Clostridium difficile. Front Microbiol. 2018;9:2953. DOI: 10.3389/fmicb.2018.02953
  • 79. Lv Z., Wang B., Zhou X., Wang F., Xie Y., Zheng H., et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: a meta-analysis. Exp Ther Med. 2015;9(3):707-716. DOI: 10.3892/etm.2015.2174
  • 80. Tong J.L., Ran Z.H., Shen J., Zhang C.X., Xiao S.D. Metaanalysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25(2):155-168. DOI: 10.1111/j.13652036.2006.03179.x
  • 81. Wang Z.H., Gao Q.Y., Fang J.Y. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47(1):25-32. DOI: 10.1097/MCG.0b013e318266f6cf
  • 82. Zhang M.M., Qian W., Qin Y.Y., He J., Zhou Y.H. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol. 2015;21(14):4345-4357. DOI: 10.3748/wjg.v21.i14.4345
  • 83. Zheng X., Lyu L., Mei Z. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. Rev Esp Enferm Dig. 2013;105(8):445-453. DOI: 10.4321/s113001082013000800002
  • 84. Zhu R., Chen K., Zheng Y.Y., Zhang H.W., Wang J.S., Xia Y.J., et al. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World J Gastroenterol. 2014;20(47):18013-18021. DOI: 10.3748/wjg.v20.i47.18013
  • 85. Dang Y., Reinhardt J.D., Zhou X., Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PloS One. 2014;9(11):e111030. DOI: 10.1371/journal.pone.0111030
  • 86. McFarland L.V., Huang Y., Wang L., Malfertheiner P. Systematic review and meta-analysis: multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United European Gastroenterol J. 2016;4(4):546-561. DOI: 10.1177/2050640615617358
  • 87. McFarland L.V., Malfertheiner P., Huang Y., Wang L. Metaanalysis of single strain probiotics for the eradication of Helicobacter pylori and prevention of adverse events. World J Metaanal. 2015;3(2):97-117. DOI: 10.13105/wjma.v3.i2.97
  • 88. Gotteland M., Poliak L., Cruchet S., Brunser O. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori. Acta Paediatr. 2005;94(12):17471751. DOI: 10.1111/j.1651-2227.2005.tb01848.x
  • 89. Losurdo G., Cubisino R., Barone M., Principi M, Leandro G., Ierardi E., et al. Probiotic monotherapy and Helicobacter pylori eradication: a systematic review with pooled-data analysis. World J Gastroenterol. 2018;24(1):139-149. DOI: 10.3748/wjg.v24.i1.139
  • 90. Rosania R., Minenna M.F., Giorgio F., Facciorusso A., De Francesco V., Hassan C., et al. Probiotic multistrain treatment may eradicate Helicobacter pylori from the stomach of dyspeptics: a placebo-controlled pilot study. Inflamm Allergy Drug Targets. 2012;11(3):244-249. DOI: 10.2174/187152812800392698
  • 91. Ianiro G., Bruno G., Lopetuso L., Beghella F.B., Laterza L., D’Aversa F., et al. Role of yeasts in healthy and impaired gut microbiota: the gut mycome. Curr Pharm Des. 2014;20(28):4565-4569. DOI: 10.2174/13816128113196660723
  • 92. Szajewska H., Horvath A., Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2015;41(12):12371245. DOI: 10.1111/apt.13214
  • 93. Myllyluoma E., Kajander K., Mikkola H., Kyronpalo S., Rasmussen M., Kankuri E., et al. Probiotic intervention decreases serum gastrin-17 in Helicobacter pylori infection. Dig Liver Dis. 2007;39(6):516-523. DOI: 10.1016/j.dld.2007.02.015
  • 94. Francavilla R., Lionetti E., Castellaneta S.P., Magista A.M., Maurogiovanni G., Bucci N., et al. Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter. 2008;13(2):127-134. DOI: 10.1111/j.1523-5378.2008.00593.x
  • 95. Zagari R.M., Pozzato P., Martuzzi C., Fuccio L., Martinelli G., Roda E., et al. 13C-urea breath test to assess Helicobacter pylori bacterial load. Helicobacter. 2005; 10(6):615-619. DOI: 10.1111/j.1523-5378.2005.00358.x
  • 96. Dore M.P., Bibbo S., Pes G.M., Francavilla R., Graham D.Y. Role of probiotics in Helicobacter pylori eradication: lessons from a study of Lactobacillus reuteri strains DSM 17938 and ATCC PTA 6475 (Gastrus®) and a proton-pump inhibitor. Can J Infect Dis Med Microbiol. 2019;2019:3409820. DOI: 10.1155/2019/3409820
  • 97. Tyagi A.K., Prasad S. Commentary: probiotic and technological properties of Lactobacillus spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis. Front Microbiol. 2015;6:433. DOI: 10.3389/fmicb.2015.00433
  • 98. Delgado S., Leite A.M.O., Ruas-Madiedo P., Mayo B. Probiotic and technological properties of Lactobacillus spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis. Front Microbiol. 2014;5:766. DOI: 10.3389/fmicb.2014.00766
  • 99. Mehling H., Busjahn A. Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to Helicobacter pylori control in humans. Nutrients. 2013;5(8):3062-3073. DOI: 10.3390/nu5083062
  • 100. Holz C., Busjahn A., Mehling H., Arya S., Boettner M., Habibi H., et al. Significant reduction in Helicobacter pylori load in humans with non-viable Lactobacillus reuteri DSM17648: a pilot study. Probiotics Antimicrob Proteins. 2015;7(2):91-100. DOI: 10.1007/s12602-014-9181-3
  • 101. Fonseca J.D., Fernandes C.C., Cunha L.F., Zung S. Efficacy and safety of Lactobacillus reuteri in Helicobacter pylori infection. Gastroenterology. 2019;156(6):S-531-S-532. DOI: 10.1016/S0016-5085(19)38215-0
  • 102. Sykora J., Valeckova K.N., Amlerova J., Siala K., Dede P., Watkins S., et al. Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN114 001 and the eradication of H. pylori in children: a prospective randomized double-blind study. J Clin Gastroenterol. 2005;39(8):692-698. DOI: 10.1097/01.mcg.0000173855.77191.44
  • 103. Deguchi R., Nakaminami H., Rimbara E., Noguchi N., Sasatsu M., Suzuki T., et al. Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy. J Gastroenterol Hepatol. 2012;27(5):888-892. DOI: 10.1111/j.14401746.2011.06985.x
  • 104. Sachdeva A., Nagpal J. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: a systematic review and meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol. 2009;21(1):4553. DOI: 10.1097/MEG.0b013e32830d0eff
  • 105. Eslami M., Yousefi B., Kokhaei P., Moghadas A.J., Moghadam B.S., Arabkari V., et al. Are probiotics useful for therapy of Helicobacter pylori diseases? Comp Immunol Microbiol Infect Dis. 2019;64:99-108. DOI: 10.1016/j.cimid.2019.02.010
  • 106. Okamoto T., Sasaki M., Tsujikawa T., Fujiyama Y., Bamba T., Kusunoki M. Preventive efficacy of butyrate enemas and oral administration of Clostridium butyricum M588 in dextran sodium sulfate-induced colitis in rats. J Gastroenterol. 2000;35(5):341-346. DOI: 10.1007/s005350050358
  • 107. Yonezawa H., Osaki T., Hanawa T., Kurata S., Zaman C., Woo T.D.H., et al. Destructive effects of butyrate on the cell envelope of Helicobacter pylori. J Med Microbiol. 2012;61:582-589. DOI: 10.1099/jmm.0.039040-0
  • 108. Takahashi M., Taguchi H., Yamaguchi H., Osaki T., Kamiya S. Studies of the effect of Clostridium butyricum on Helicobacter pylori in several test models including gnotobiotic mice. J Med Microbiol. 2000;49(7):635-642. DOI: 10.1099/0022-1317-49-7-635
  • 109. Imase K., Takahashi M., Tanaka A., Tokunaga K., Sugano H., Tanaka M., et al. Efficacy of Clostridium butyricum preparation concomitantly with Helicobacter pylori eradication therapy in relation to changes in the intestinal microbiota. Microbiol Immunol. 2008;52(3):156161. DOI: 10.1111/j.1348-0421.2008.00026.x
  • 110. Gareau M.G., Sherman P.M., Walker W.A. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol. 2010;7(9):503-514. DOI: 10.1038/nrgastro.2010.117
  • 111. Wu L., Wang Z., Sun G., Peng L., Lu Z., Yan B., et al. Effects of anti-H.pylori triple therapy and a probiotic complex on intestinal microbiota in duodenal ulcer. Sci Rep. 2019;9(1):12874. DOI: 10.1038/s41598-01949415-3
  • 112. Yang C., Liang L., Lv P., Liu L., Wang S., Wang Z., et al. Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication: a randomized double-blind placebo-controlled trial. Helicobacter. 2021;26(6):e12856. DOI: 10.1111/hel.12856
  • 113. Chen M.J., Chen C.C., Huang Y.C., Tseng C.C., Hsu J.T., Lin Y.F., et al. The efficacy of Lactobacillus acidophilus and rhamnosus in the reduction of bacterial load of Helicobacter pylori and modification of gut microbiota – a doubleblind, placebo-controlled, randomized trial. Helicobacter. 2021;26(6):e12857. DOI: 10.1111/hel.12857
  • 114. Naghibzadeh N., Salmani F., Nomiri S., Tavakoli T. Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial. BMC Gastroenterol. 2022;22(1):107. DOI: 10.1186/s12876-022-02187-z
  • 115. Hablass F.H., Lashen S.A., Alsayed E.A. Efficacy of lactoferrin with standard triple therapy or sequential therapy for Helicobacter pylori eradication: a randomized controlled trial. Turk J Gastroenterol. 2021;32(9):742749. DOI: 10.5152/tjg.2021.20923
  • 116. Viazis N., Argyriou K., Kotzampassi K., Christodoulou D.K., Apostolopoulos P., Georgopoulos S.D., et al. A fourprobiotics regimen combined with a standard Helicobacter pylori-eradication treatment reduces side effects and increases eradication rates. Nutrients. 2022;14(3):632. DOI: 10.3390/nu14030632
  • 117. Cifuentes S.G., Prado M.B., Fornasini M., Cohen H., Baldeуn M.E., Cоrdenas P.A. Saccharomyces boulardii CNCM I-745 supplementation modifies the fecal resistome during Helicobacter pylori eradication therapy. Helicobacter. 2022;27(2):e12870. DOI: 10.1111/hel.12870
  • 118. Guillemard E., Poirel M., Schafer F., Quinquis L., Rossoni C., Keicher C., et al. A randomised, controlled trial: effect of a multi-strain fermented milk on the gut microbiota recovery after Helicobacter pylori therapy. Nutrients. 2021;13(9):3171. DOI: 10.3390/nu13093171
  • 119. Venkatesan T. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebocontrolled trial. Nutr Clin Pract. 2008;23(6):662-663. DOI: 10.1177/0884533608326323
  • 120. Besselink M.G., van Santvoort H.C., Buskens E., Boermeester M.A., van Goor H., Timmerman H.M., et al., and Dutch Acute Pancreatitis Study Group. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371(9613):651-659. DOI: 10.1016/S01406736(08)60207-X
  • 121. Chicherin I.Yu., Pogorel`skij I.P., Lundovskix I.A., Pozolotina N.V., Gavrilov K.E., Darmov I.V., et al. The role of probiotic microorganisms in translocation of intestinal microbiota in the peritoneal cavity and the bloodstream of experimental animals. Infekcionny`e bolezni. 2015;13(4):43-52. Russian.
  • 122. Chicherin I.Yu., Pogorel`skij I.P., Lundovskix I.A., Darmov I.V., Gavrilov K.E., Gorshkov A.S., et al. Translocation of intestinal microbiota. Zhurnal mezhdunarodnoj mediciny. 2016;2(19):24-31. Russian.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared